10 Best Low Volatility Stocks to Invest in Now

2. Thermo Fisher Scientific Inc. (NYSE:TMO)

Number of Hedge Fund Holders: 108

5-year Beta (Monthly): 0.78

Thermo Fisher Scientific Inc. (NYSE:TMO) offers a range of products and services in life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products, catering to various markets worldwide.

Thermo Fisher (NYSE:TMO) reported mixed earnings on October 24, with EPS of $5.28 slightly exceeding the estimates but revenue of $10.6 billion lagged the forecasts by $30 million. The company raised its full-year EPS guidance to a range of $21.35 to $22.07, compared to the prior outlook of $21.29 to $22.07. The company’s revenue guidance remained unchanged between the range of $42.4 billion to $43.3 billion.

Despite mixed results, analysts view the stock in a positive light. As reported by TipRanks on October 25, Morgan Stanley’s Tejas Savant kept a Buy rating on Thermo Fisher (NYSE:TMO) with a $670 price target based on the company’s steady third-quarter performance, with organizational revenue growing sequentially for three quarters despite pandemic challenges.

Adjusted EPS also exceeded expectations, aided by strong cost control and reduced interest expenses. Strategic investments are boosting productivity, and the company’s cautious management of market challenges suggests a promising trajectory through 2025, despite some uncertainty in the broader market.

Moreover, on October 24, The Fly reported that RBC Capital maintained an Outperform rating on the company stock but reduced the company’s price target from $767 to $718. The firm found the insights from the company’s Q3 earnings call to be more optimistic than the actual results. It continues to have a favorable view of the stock and noted that the Life Sciences Solutions segment is experiencing positive momentum in bioproduction. Additionally, sales in the Laboratory Products and Biopharma Services segments are not showing signs of a slowdown in the biotech industry, according to the analyst’s commentary to investors.